Victor Giannini, Pharm.D., RPh.

New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare

3

We want to call your attention to a timely new series on AJMC® Peer Exchange® peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel discussion on the use of CDK4/6 inhibitors in high-risk early breast cancer. With insights from renowned experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO, this series covers crucial updates, best practices in managing toxicity profiles, and navigating financial challenges to optimize patient outcomes. Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates

2

In 2024, 5 emerging BTK inhibitors are undergoing late-phase clinical investigation for #multiplesclerosis. Most clinicians are likely unaware of the clinical data regarding their use in MS. Dive into the data and earn free #CME here: https://bit.ly/4gViIVp #MedEd #FOAMed

2

#NEW from Juliana "Julie" Reed in STAT: The PBM Monopoly intentionally forces Americans onto high-cost, high-rebate drugs. Greater use of biosimilars can save the U.S. health care system up to $133 billion by 2025. Yet these savings are being completely left on the table because PBMs prioritize high-cost, high-rebate drugs over lower-cost biosimilars. It is time we put patients first. Read the full piece below: #biosimilars #drugpricing #FTC #PBMs #patients https://lnkd.in/ePsQ7edd

35

Thoughts on this? >> Northwell debuts gene therapy with $2.8M price tag for patients - Crain's New York Business >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #healthcare #biotech

1

Check out AscellaHealth’s Q2 Specialty & Rare Pipeline Digest featuring the latest updates on recent specialty drug approvals, upcoming reviews, CGT and biosimilar pipelines. If you haven’t already, make sure to subscribe today: https://lnkd.in/epMupw4w #specialtypharmacy #pharmaceuticals #raredisease #FollowAscellaHealth 

2

AURLUMYN™ (iloprost) injection by SERB Pharmaceuticals is now available exclusively through FFF Enterprises. As the only FDA-approved treatment for severe frostbite, AURLUMYN™ helps reduce the risk of digit amputations, offering a critical solution for adults with this rare yet debilitating condition. Learn more at https://bit.ly/4fmocGJ #FFFEnterprises #HelpingHealthcareCare #Aurlumyn #EmergencyCare #Frostbite #CriticalCare #EmergencyRoom

13

As we approach the end of 2024, it's a perfect time to reflect on the remarkable growth we've experienced this year. Shared from Barry Patel, Pharm.D is a message from our Co-Founders, Barry & Wade, on the Galt Journey; a journey of resilience, innovation, and determination. Full article can be found at the link below. https://lnkd.in/d3dVTFXH

5

1 Comment

As we approach the end of 2024, it's a perfect time to reflect on the remarkable growth we've experienced this year. Shared from Barry Patel, Pharm.D is a message from our Co-Founders, Barry & Wade, on the Galt Journey; a journey of resilience, innovation, and determination. Full article can be found at the link below. https://lnkd.in/djHdgz5z

3

Can Madrigal Pharmaceuticals' Rezdiffra keep its lead in the growing metabolic dysfunction–associated steatohepatitis (MASH) market? To find out we are launching a poll to #endocrinologists, #gastroenterologists and #hepatologists. Learn more here: https://lnkd.in/ds8VP8Xy #MASH #medicalaffairs #pharmaceuticals #regulatoryaffairs

5

Will you be at #AMCP2024 this year? This Wednesday, April 17th at 10:45 CT Alnylam’s Sami Nasrawi, PharmD is leading a spotlight presentation: “ATTR Amyloidosis - Disease State Overview.” Join us in Theater 2 to learn more about ATTR #Amyloidosis epidemiology, clinical presentation and diagnosis of both cardiomyopathy and polyneuropathy manifestations. Learn more about AMCP: https://bit.ly/49BEjx1

123

The FDA, NKF, and ASN are leading the charge to move from C-G eCrCL to race-free eGFR equations for medication-related decisions. In this paper, AKHOMM leaders explain how this change impacts kidney care.

25

Interested in the latest insights from oncologists ahead of #ASCO24? 🚀 Check out perspectives on this year's conference from the front lines of cancer care in our latest blog post: https://lnkd.in/eYupPznU #ASCO24 #OncologyInsights #HealthcareMarketResearch

24

Association of Northern California Oncologists (ANCO)’s ASCO24 highlights panel discussion with Eric Small American Society of Clinical Oncology (ASCO) #ANCO #ASCO #ASCO24 #Cancer #OncoDaily #Oncology

19